投資概要
華潤醫藥是中國領先的綜合醫藥公司，公司業務涵蓋醫藥產品的製藥、分銷、零售和
其他業務營運，產品組合包括化學藥、中藥、生物藥以及營養保健品等廣泛的治療領
域，在研產品覆蓋心血管系統、呼吸系統、抗腫瘤、中樞神經系統、免疫系統、泌尿
生殖系統、血液、消化道和新陳代謝、抗感染、中藥經典名方等。華潤醫藥公佈 2021
年全年業績，公司實現總收入 2,368.06 億港元，同比增長 18.2%，主要得益於疫情緩
解，業績實現恢復性增長。尤其以醫藥分銷業務對於收入增長貢獻佔比最大。整體淨
利潤達到 66.47 億港元，同比增長 24.9%；歸屬於母公司所有者淨利潤 37.69 億港
元，同比增長 14.3%。

Investment highlights
CR Pharmaceutical is a leading integrated pharmaceutical company in China specializing in the
pharmaceutical, distribution and retail of medicines. Its product portfolio includes chemical
drugs, traditional Chinese medicines, biological drugs, and nutraceutical products. Its product
coverage contains cardiovascular system, respiratory system, anti-tumor, central nervous
system, immune system, genitourinary system, blood, digestive tract and metabolism, antiinfection, traditional Chinese medicine, etc. CR Pharmaceutical announced its 2021 annual
results that the company achieved total revenue of HK$236.806 billion, with a YoY increase of
18.2%. The increase was mainly due to the relief of the epidemic and the recovery in
performance. In particular, the pharmaceutical distribution business accounted for the largest
contribution to revenue growth. The overall net profit reached HK$6.647 billion, with a YoY
increase of 24.9%; The net profit attributable to owners of the parent company was HK$3.769
billion, with a YoY increase of 14.3%.